Aristotle Atlantic Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Aristotle Atlantic Partners's VRTX Position: Q3 2026 in Review
Aristotle Atlantic Partners increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q3 2026, buying an estimated $3.02M and bringing the position to 43,390 shares worth $22.7M. The position accounts for 0.89% of the portfolio, ranked #37.
Aristotle Atlantic Partners first reported a position in VRTX in Q2 2021 and has held it in 20 quarters since. The position peaked at $25.2M in Q3 2024. 1,772 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Aristotle Atlantic Partners held 43,390 shares of Vertex Pharmaceuticals worth $22.7M as of Q3 2026.
- Aristotle Atlantic Partners bought 5,901 Vertex Pharmaceuticals shares in Q3 2026, an estimated $3.02M.
- Vertex Pharmaceuticals made up 0.89% of Aristotle Atlantic Partners's portfolio in Q3 2026, its #37 holding.
- Aristotle Atlantic Partners first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
- Aristotle Atlantic Partners's Vertex Pharmaceuticals position peaked at $25.2M in Q3 2024.
- 1,772 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Aristotle Atlantic Partners's 13F filing for Q3 2026, filed 16 Nov 2026.